Literature DB >> 19423769

Use of probiotics in the management of chemotherapy-induced diarrhea: a case study.

Samia Abd El-Atti1, Kelley Wasicek, Scott Mark, Refaat Hegazi.   

Abstract

Gastrointestinal disturbances (particularly diarrhea) are often induced in response to cancer treatments such as chemotherapy or radiation. Oral chemotherapeutic agents can induce diarrhea by damaging the intestinal lining. Two common oral drugs used in cancer treatment that are known to have gastrointestinal side effects are capecitabine and lapatinib. In this brief communication, the authors discuss a case study of a stage IV breast cancer patient whose chemotherapy-induced diarrhea was treated successfully with a multispecies combination of probiotics. This is a unique study in which grade 3 chemotherapy-induced diarrhea (characterized by 7-9 stools per day and associated with incontinence and abdominal cramping) was treated with only a multispecies combination of probiotics. Probiotics have been used to treat diarrhea in patients with irritable bowel syndrome, ulcerative colitis, pouchitis, and Crohn's disease. More recently, probiotics have been used to treat chemotherapy-induced diarrhea in colon cancer patients. This case study demonstrates that the probiotics can also be used to treat severe cases of chemotherapy-induced diarrhea in breast cancer patients. The use of different probiotics in gastrointestinal diseases is an increasingly important area of study, and more research into this area is needed. This study demonstrates that probiotics should be considered for advanced breast cancer patients with chemotherapy-induced diarrhea.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423769     DOI: 10.1177/0148607109332004

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  6 in total

Review 1.  Systematic review of agents for the management of gastrointestinal mucositis in cancer patients.

Authors:  Rachel J Gibson; Dorothy M K Keefe; Rajesh V Lalla; Emma Bateman; Nicole Blijlevens; Margot Fijlstra; Emily E King; Andrea M Stringer; Walter J F M van der Velden; Roger Yazbeck; Sharon Elad; Joanne M Bowen
Journal:  Support Care Cancer       Date:  2012-11-10       Impact factor: 3.603

Review 2.  Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.

Authors:  Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

3.  Milk fermented by Lactobacillus casei CRL431 administered as an immune adjuvant in models of breast cancer and metastasis under chemotherapy.

Authors:  V E Méndez Utz; D Pérez Visñuk; G Perdigón; A de Moreno de LeBlanc
Journal:  Appl Microbiol Biotechnol       Date:  2020-11-18       Impact factor: 4.813

4.  Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting.

Authors:  Jutta Zwielehner; Cornelia Lassl; Berit Hippe; Angelika Pointner; Olivier J Switzeny; Marlene Remely; Elvira Kitzweger; Reinhard Ruckser; Alexander G Haslberger
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

Review 5.  Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities.

Authors:  Mansour Sedighi; Abed Zahedi Bialvaei; Michael R Hamblin; Elnaz Ohadi; Arezoo Asadi; Masoumeh Halajzadeh; Vahid Lohrasbi; Nima Mohammadzadeh; Taghi Amiriani; Marcela Krutova; Abolfazl Amini; Ebrahim Kouhsari
Journal:  Cancer Med       Date:  2019-04-05       Impact factor: 4.452

Review 6.  Diet and nutrition in cancer survivorship and palliative care.

Authors:  Anthony J Bazzan; Andrew B Newberg; William C Cho; Daniel A Monti
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-30       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.